Moderna (NASDAQ:MRNA) held the mantel during the COVID-19 pandemic, but as the pharma landscape shifts, the company must adapt. The latest quarterly report, however, brings a glimmer of hope for shareholders. Looking ahead to 2024, I foresee a major turnaround for MRNA stock.
Moderna’s Surprise Profit in Q4-FY2023
Moderna’s stock soared by 13.5%, surpassing $100, following its Q4-FY2023 financial report. The company’s $2.8 billion revenue exceeded the forecast, indicating a strong performance. While COVID-19 vaccine sales declined, the company’s focus on non-COVID-19 products is promising.
Moderna’s Shift Beyond COVID-19
CEO Stéphane Bancel referred to 2023 as a “year of transition,” acknowledging the challenges in commercializing COVID-19 vaccines. Moderna’s pipeline holds potential, notably the mRNA-1345 RSV vaccine. The expected regulatory approval in 2024 foretells a promising revenue stream for the company.
Analysts’ Take on Moderna Stock
Analysts lean towards a Moderate Buy for MRNA stock, with an average price target of $131.38, signaling a 32.1% upside potential. Notably, analyst Hartaj Singh of Oppenheimer holds a remarkable track record on Moderna, adding confidence for prospective investors.
Why Consider Moderna Stock?
Despite a significant rally, Moderna stock exhibits substantial growth potential. The company’s unexpected profit and earnings beat in the latest quarter are commendable, positioning MRNA stock favorably for prospective investment.
Disclosure
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
